Clinical trial · Interventional
Hormone Replacement Therapy in Relieving Menopausal Symptoms in Postmenopausal Women With Previous Stage I or Stage II Breast Cancer
UK Trial Of Hormone Replacement Therapy (HRT) In Women With A History Of Early Stage Breast Cancer
NCT00079248CI-TRIAL-00002299unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Hormone replacement therapy may be effective in relieving symptoms of menopause, such as hot flashes, night sweats, and vaginal dryness, without causing a recurrence of breast cancer. PURPOSE: This randomized clinical trial is studying hormone replacement therapy to see how well it works in relieving symptoms of menopause in postmenopausal women with previous stage I or stage II breast cancer.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Hot Flashes | — | UNRESOLVED | — |
| Menopausal Symptoms | — | UNRESOLVED | — |
| Osteoporosis | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| conjugated estrogens | Drug | — | UNRESOLVED |
| therapeutic progesterone | Biological | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Prior diagnosis of stage I or II breast cancer
* No clinical evidence of recurrence
* Meets criteria for 1 of the following:
* Amenorrheic for at least the past 6 months
* Radiotherapy- or chemically-induced ovarian suppression allowed
* Prior surgical bilateral oophorectomy
* Experiencing vasomotor symptoms (i.e., hot flashes or night sweats) with or without vaginal dryness
* No undiagnosed postmenopausal bleeding
* No ductal carcinoma in situ or lobular carcinoma in situ alone
* Hormone receptor status:
* Not specified
PATIENT CHARACTERISTICS:
Age
* Postmenopausal
Sex
* Female
Menopausal status
* Postmenopausal
Performance status
* Not specified
Life expectancy
* Not specified
Hematopoietic
* Not specified
Hepatic
* No severe, active liver disease with abnormal liver function tests
* No acute, intermittent porphyria
* Fibrinolysis and coagulation normal
Renal
* Not specified
Cardiovascular
* No prior deep vein thrombosis
* Thrombophlebitis or superficial phlebitis alone allowed
* No prior retinal vein thrombosis
Pulmonary
* No prior pulmonary embolism
Other
* Not pregnant
* No prior alcohol, drug, or chemical abuse
* No other prior or concurrent malignancy except nonmelanoma skin cancer or carcinoma in situ of the cervix
PRIOR CONCURRENT THERAPY:
Biologic therapy
* Not specified
Chemotherapy
* No concurrent chemotherapy
Endocrine therapy
* More than 3 months since prior oral or transdermal hormone replacement therapy (HRT)
* More than 5 years since prior HRT implant
* No other concurrent HRT
* No concurrent gonadotropin-releasing hormone agonists (e.g., goserelin) if less than 2 years of planned treatment remains
* No other concurrent low-dose progestins
* No concurrent tibolone
* No concurrent phytoestrogens (e.g., black cohosh, red clover, or soy)
Radiotherapy
* See Disease Characteristics
Surgery
* See Disease Characteristics
Other
* No concurrent Hypericum perforatum (St. John's wort)References
Publications (0)
Data not yet available
No reference posted for this study.